-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Upgrades Gilead Sciences to Buy, Raises Price Target to $155

Benzinga·07/06/2026 09:51:26
Listen to the news
HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises the price target from $133 to $155.